Hematopoietic stem cell self-renewal

Hematopoietic stem cell (HSC) self-renewal is the essential biological process by which a stem cell divides to produce at least one daughter cell that retains the same undifferentiated state and multi-lineage potential as the parent cell. This process is critical for maintaining the lifelong supply of blood cells and is tightly regulated by a complex interplay of intrinsic genetic factors (such as BMI1, HOXB4, and GATA2) and extrinsic signals from the bone marrow niche (including Wnt, Notch, and Hedgehog signaling pathways). In clinical medicine, the ability to pharmacologically trigger HSC self-renewal ex vivo is a major goal for improving the success of hematopoietic stem cell segmentations and gene therapies, particularly when using limited sources like umbilical cord blood. While not a single molecular target itself, the pathways governing self-renewal are targeted by small molecules like SR1 (Aryl hydrocarbon receptor antagonist) and UM171 to expand HSC populations for therapeutic use.

Other names

HSC self-renewalHematopoietic stem cell maintenanceHSC expansion

Drugs typically modulate this process by antagonizing the Aryl hydrocarbon receptor (AhR), inhibiting the CoREST complex, or activating Wnt/Notch signaling pathways to prevent differentiation and promote symmetric division.